ASH 2020 | Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMM
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results from the multicentre, double-blind, phase III TOURMALINE-MM4 trial (NCT02312258) comparing the proteosome inhibitor ixazomib with placebo in elderly patients with non-transplant newly diagnosed multiple myeloma (NDMM). The prognostic value of undetectable MRD in the setting of pre-maintenance therapy in transplant-ineligible patients was highlighted by the longitudinal MRD assessment during post-induction maintenance therapy. Maintenance treatment with ixazomib following best response to induction can benefit progression-free survival (PFS) in MRD-positive patients. This interview took place during the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
